Skip Navigation



Carcinogenesis Advance Access published online on November 5, 2009
Carcinogenesis, doi:10.1093/carcin/bgp265
This Article
Right arrow Advance Access manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Niu, J.
Right arrow Articles by Wei, Q.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niu, J.
Right arrow Articles by Wei, Q.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Genetic Polymorphisms in the PTPN13 gene and Risk of Squamous Cell Carcinoma of Head and Neck

Jiangong Niu1, Yu-Jing Huang1, Li-E Wang1, Erich M. Sturgis1,2 and Qingyi Wei1,*

1 Department of Epidemiology
2 Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA

* To whom correspondence should be addressed. Tel: +1 713 745 2481; Fax: +1 713 563 0999; Email: qwei{at}mdanderson.org

Fas-associated phosphatase 1 (FAP-1) is encoded by the protein tyrosine phosphatase, non-receptor type 13 (PTPN13) gene and attributes to the resistance to Fas-mediated apoptosis in several tumors, including squamous cell carcinoma of head and neck (SCCHN). However, no epidemiological studies have investigated the roles of PTPN13 polymorphisms in SCCHN risk. In this hospital based case-control study of 1069 SCCHN patients and 1102 non-Hispanic white cancer-free controls, we evaluated the associations between three single nucleotide polymorphisms (SNPs) c.4068 T>G F1356L (rs10033029), c.4566 A>G I1522M (rs2230600) and c.6241 T>G Y2081D (rs989902) located in the coding region of PTPN13 and SCCHN risk. We found that a significantly increased SCCHN risk was associated with c.4566 I1522M GG genotype (OR = 1.89, 95% CI = 1.27-2.79) and c.6241 Y2081D GT genotype (OR = 1.26, 95% CI = 1.03-1.53) compared with the c.4566 I1522M AA and c.6241 Y2081D TT genotypes, respectively. Further stratified analyses showed that risk associated with c.4566 I1522M GG genotype was more profound in the subgroups of young (≤57 years), males, never smokers, current drinkers, and patients with pharyngeal cancer; that risk associated with c.6241 Y2081D GT genotype persisted in subgroups of old (>57 years), males, current drinkers, and patients with pharyngeal and laryngeal cancers; and that risk associated with c.6241 Y2081D GG genotype was borderline in patients with laryngeal cancer. In conclusion, polymorphisms in the PTPN13 coding region may be biomarkers for susceptibility to SCCHN in US populations.

Key Words: Apoptosis • Fas-associated phosphatase 1 • Head and neck cancer • Polymorphism • Susceptibility

Received July 2, 2009; revised September 30, 2009; accepted October 17, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.